


# An automation platform for the production & characterization of patient derived monoclonal antibodies



## Introduction

- Currently our platform focuses on the production of auto-antibodies from single B-cells
- Autoantibodies target endogenous epitopes, are associated with different diseases, and cause a variety of pathologies
- We investigate B-cells and respective (auto-) antibodies from the human cerebrospinal fluid (CSF) and concentrate on cohorts with neurological disorders
- The aim is a better understanding of autoantibodies in neurological disorders and the provision of new research tools & novel approaches towards diagnosis and therapy

## mAB Production Workflow




## Initial mAB Characterization with Primary Human or iPS Cell Models


Check out our BBB model: Fengler et. al

	mAB 1	mAB 2	mAB 3	mAB 4	mAB 5	mAB 6	mAB 7	mAB 8	example pictures taken with CV8000
BMEC (brain microvascular endothelial cells)	X	✓	X	X	X	X	✓	✓	
pericytes	X	X	✓	X	X	X	✓	✓	
astrocytes	X	X	X	✓	X	X	✓	✓	
smooth muscle cells	X	X	X	X	✓	X	✓	✓	
PBMCs	X	X	X	X	X	✓	X	✓	
neurons	X	X	X	X	X	X	✓	✓	

## Automated Production



## Summary



**Dominik Stappert\***  
 Sven Fengler\*  
 Malwina Kotowicz\*  
 Jakob Kreye#  
 Birgit Kurkowsky\*

Anja Meyer-Berhorn\*  
 Josephine Blersch\*  
 Wera Roth\*  
 Momsen Reincke#

Scott Van Hoff#  
 Harald Prüss#  
 Philip Denner\*  
 Eugenio Fava\*

\*German Center for Neurodegenerative Diseases (DZNE), CRFS, Bonn, Germany

#German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

**BaoBab**  
 a Helmholtz Innovation Lab

